KMT2A Rearrangement Clinical Trials

6 recruitingLast updated: June 18, 2026

There are 6 actively recruiting kmt2a rearrangement clinical trials across 2 countries. Studies span Phase 1, Phase 2. Top locations include Suzhou, Jiangsu, China, Columbus, Ohio, United States, Chapel Hill, North Carolina, United States. Updated daily from ClinicalTrials.gov.


KMT2A Rearrangement Trials at a Glance

6 actively recruiting trials for kmt2a rearrangement are listed on ClinicalTrialsFinder across 6 cities in 2 countries. The largest study group is Phase 1 with 4 trials, with the heaviest enrollment activity in Suzhou, Columbus, and Chapel Hill. Lead sponsors running kmt2a rearrangement studies include The First Affiliated Hospital of Soochow University, Massachusetts General Hospital, and National Cancer Institute (NCI).

Browse kmt2a rearrangement trials by phase

Treatments under study

About KMT2A Rearrangement Clinical Trials

Looking for clinical trials for KMT2A Rearrangement? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new KMT2A Rearrangement trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about KMT2A Rearrangement clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 1

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaAcute Myeloid Leukemia With KMT2A Rearrangement+1 more
National Cancer Institute (NCI)38 enrolled22 locationsNCT05886049
Recruiting
Phase 1

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaAcute Myeloid Leukemia With FLT3/ITD Mutation+2 more
Uma Borate30 enrolled4 locationsNCT06222580
Recruiting

A Real-world Study on the Efficacy and Safety of Menin Inhibitors as Maintenance After Allo-HSCT

Acute LeukemiaMenin InhibitorsPost Hematopoietic Stem Cell Transplantation+4 more
The First Affiliated Hospital of Soochow University20 enrolled1 locationNCT07559695
Recruiting
Phase 1

Ziftomenib Maintenance Post Allo-HCT

Acute Myeloid LeukemiaAcute Myeloid Leukemia in RemissionKMT2A Rearrangement+1 more
Massachusetts General Hospital22 enrolled2 locationsNCT06440135
Recruiting
Phase 1

BY002 IIT Study in R/R Acute Leukemia

Acute LeukemiaKMT2A Rearrangements or NPM1 Mutations Acute Leukemia
The First Affiliated Hospital of Soochow University18 enrolled1 locationNCT07270770
Recruiting
Phase 2

Phase 2 Trial of BN104 as Post-HSCT Maintenance in Acute Leukemia

Acute LeukemiaMenin InhibitorsPost Hematopoietic Stem Cell Transplantation+4 more
The First Affiliated Hospital of Soochow University60 enrolled1 locationNCT07101497